Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Lensar, Inc. LNSR

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$58.4M
▲ 9.2% YoY
$-34.3M
$-14.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

As of December 31, 2025, LENSAR had approximately 150 employees that support its manufacturing, research and development, commercial and administrative functions. Primarily all of the company's workforce is based at its corporate headquarters in Orlando, Florida. LENSAR was incorporated in the State of Delaware on August 20, 2004 and became a direct, majority-owned subsidiary of PDL BioPharma, Inc. in 2017. As of December 31, 2025, the company owned approximately 292 issued patents and 105 pending patent applications globally.

Written from the business description in LENSAR, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 58.4M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 58.4 · Net income -34.3
25.0M50.0M-15.0M-30.0M
201920222025
Compound annual growth
+18.2%
+17.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−59 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -42.1% · Net -58.7%
-20%-40%-60%
201920222025
ROE
FY2024 · ROE -164.0%
-50%-100%-150%
201920222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -60%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -14.9
-10M-20M
201920222025

Total assetsUSD 71.4M
EquityUSD -26.0M
CashUSD 13.0M
Current ratio1.15×

Equity funds -36% of total assets.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
LNSR, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.10.10.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−2.87−2.73−1.31−1.96−2.09−4.28−13.70
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %—−164.0−38.1−41.1−32.1——
Shares out B0.010.010.010.010.010.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image